Radium-223 for advanced hormone-sensitive prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if adding radium-223 after initial hormone therapy, chemotherapy, and darolutamide can help control high-volume metastatic prostate cancer that has spread to the bones. It aims to see if this extra treatment can further delay progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced prostate cancer that has spread to the bones (at least 4 spots on a bone scan) and you have already received triple therapy (hormone therapy, docetaxel chemotherapy, and darolutamide).
- You finished docetaxel within 12 weeks of starting radium-223 and did not get worse after completing triple therapy.
- Your pain from the cancer is none or mild (worst pain under 4 on a 0-10 scale).
- You are willing to start or continue bone-strengthening medication (bisphosphonate or denosumab) with calcium and vitamin D before the first dose of radium-223.
- You have adequate organ and bone marrow function (like good kidney, liver, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Hear when a new Metastatic Hormone-Sensitive Prostate Cance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.